Anticancer agent 241 (HZ1) is an orally active first-in-class cyclin-dependent kinase like 3 (CDKL3)-specific inhibitor. Anticancer agent 241 shows a strong tumor-suppressing effect, and has the potential to overcome the resistance of CDK4/6 inhibitor[1].
in vivo
Anticancer agent 241 (HZ1; 1 mg/kg; oral gavage; daily for 12-14 days) has anticancer activity in a mouse model of colon cancer[1].
Animal Model:
6-week-old female athymic nude mice injected with DLD-1 cells[1]
Dosage:
1 mg/kg
Administration:
Oral gavage; daily for 12-14 days
Result:
Suppressed tumor volume in a mouse model of colon cancer.
References
[1] Haijiao Zhang, et al. CDKL3 is a targetable regulator of cell cycle progression in cancers. J Clin Invest. 2024 Jul 4:e178428. DOI:10.1172/JCI178428
